Effects of extended-release niacin with laropiprant in high-risk patients.
By M. Landray, R. Haynes, J. Hopewell, S. Parish, Theingi Aung, J. Tomson, K. Wallendszus, M. Craig, Lixin Jiang, R. Collins and 1 more. New England Journal of Medicine, 2014
1,436 citations recorded by the source corpus.
Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/9ccce1d5810f7ee51726f08bc8c2b060038e9ed2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, neutral): “on Global Health Outcomes [AIM-HIGH] and Heart Protection Study 2—Treatment of HDL to Reduce the Incidence of Vascular Events [HPS2-THRIVE]) failed to show CVD protection during the 3- and 4-year trial periods, respectively (212,213); by design, betweengroup differences in LDL-C were nominal at 5 mg”
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, methodology): “Niacin did not reduce strokeover long-termfollow-up inpatientswithCVDintheAIM-HIGH and HPS2-THRIVE trials.(251,252) In fact, the increased rate of ischaemic stroke in the AIM-HIGH trial and the trend (P 1⁄4 0.”
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement (2022, background): “Niacin is not recommended given the lack of clinical benefit in two outcomes studies.(200,201) Current data also do not support targeting aspirin use based on Lp(a) levels.”